Receive up-to-the-minute news updates on the hottest topics with NewsHub. Install now.

AbbVie doubles down on cancer project with biotech group Argenx

August 22, 2018 7:48 AM
113 0

BRUSSELS (Reuters) - Biotech group Argenx said on Wednesday U.S. pharma group AbbVie had exercised an exclusive option to develop and commercialize one of its experimental drugs which could lead to payments of up to $625 million.

Following the announcement, Argenx shares rose by more than 6 percent in early trading.

Read more

Share in social networks:

Comments - 0